Therapy to target renal cell carcinoma using 131I-labeled B7-H3 monoclonal antibody

Abstract

// Gongcheng Wang 1,* , Ziyu Wu 2,* , Yunyan Wang 1,* , Xueqin Li 3 , Guangbo Zhang 4 and Jianquan Hou 5 1 Department of Urology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu, China 2 Department of Urology, Huai’an Hospital Affiliated of Xuzhou Medical College and Huai’an Second People’s Hospital, Huai’an, Jiangsu, China 3 Department of Gerontology, Huai’an First People’s Hospital, Nanjing Medical University, Huai’an, Jiangsu, China 4 Department of Clinical Immunology Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China 5 Department of Urology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China * These authors have contributed equally to this work Correspondence to: Jianquan Hou, email: // Keywords : B7-H3; mice, nude; renal cell carcinoma; targeting therapy; monoclonal antibody Received : July 19, 2015 Accepted : March 18, 2016 Published : April 02, 2016 Abstract B7-H3 is a tumor-associated antigen that plays a critical role in potential tumor-targeted therapy. In this study, we aimed to assess the radiobiological effect of 131 I-labeled B7-H3 monoclonal antibody ( 131 I-4H7) in nude mice with human renal cell carcinoma (RCC) and evaluate the effect of 131 I-4H7 on RCC treatment. The radiobiological activity and tumor uptake of 131 I-4H7, and its effect on tumor growth were measured. 131 I-4H7 was absorbed by the tumor and reached its maximal uptake rate (3.32% injected dose [ID]/g) at 24 h, at which point the drug concentration in the tumor was 7.36-, 2.06-, 1.80-, and 2.78-fold higher than that in muscle, kidneys, liver, and heart, respectively. Measurements and positron emission tomography–computed tomography imaging showed that tumor development was significantly inhibited by 131 I-4H7. HE staining revealed that 131 I-4H7 significantly injures tumor cells. Our results suggest that 131 I-4H7 is markedly absorbed by the tumor and did suppress the development of RCC xenografted tumors in nude mice, which might provide a new candidate for antibody-mediated targeted radiotherapy in human RCC.